|   | |
| Clinical data | |
|---|---|
| Routes of administration | Oral | 
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Elimination half-life | 106 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.428.842 | 
| Chemical and physical data | |
| Formula | C15H10BrFN2O | 
| Molar mass | 333.160 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Flubromazepam is a benzodiazepine derivative which was first synthesized in 1960, [1] but was never marketed and did not receive any further attention or study until late 2012 when it appeared on the grey market as a novel designer drug. [2] [3] [4] [5] [6] [7] [8]
It is a structural analog of phenazepam in which the chlorine atom has been replaced by a fluorine atom.
An alternate isomer, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one or "iso-flubromazepam", [9] may have been sold under the same name. [2]
 
 In the UK, flubromazepam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs. [10]
Flubromazepam, clonazolam, and flubromazolam are Schedule I controlled substances under Virginia State Law. [11]